Table 2.
Clinical characteristics of survivors and non-survivors in the BP group.
| Variable | Survivors (35) | non-survivors (51) | Statistic | P value |
|---|---|---|---|---|
| n (%) | n (%) | |||
| male gender | 25 (71.4) | 45 (88.2) | 3.872 | 0.049 |
| age, mean(y) | 67.29 ± 10.64 | 71.73 ± 16.72 | t = −1.504 | 0.136 |
| length of stay ICU, mean d | 30.51 ± 31.659 | 23.63 ± 34.175 | z = −1.579 | 0.114 |
| length of ICU prior to bacteremia | 17.34 ± 22.643 | 16.22 ± 23.466 | Z = −0.004 | 0.996 |
| mechanical ventilation | 35 (100) | 51 (100) | — | — |
| length of MV, mean d | 32.71 ± 34.335 | 21.33 ± 29.203 | z = −1.958 | 0.050 |
| length of MV prior to bacteremia | 18.23 ± 22.196 | 12.67 ± 22.924 | z = −2.105 | 0.035 |
| Co-morbidities at admission | ||||
| hypoproteinemia | 29 (82.9) | 44 (86.3) | 0.189 | 0.664 |
| ARDS | 8 (22.9) | 34 (66.7) | 15.943 | 0.000 |
| coma | 8 (22.9) | 23 (45.1) | 4.454 | 0.035 |
| wound infection | 1 (2.9) | 2 (3.9) | 0.070 | 0.792 |
| urinary tractin fection | 1 (2.9) | 0 | 1.474 | 0.225 |
| COPD | 9 (25.7) | 16 (31.4) | 0.322 | 0.570 |
| cerebral vascular disease | 5 (14.3) | 13 (25.5) | 1.574 | 0.210 |
| hypertension | 16 (45.7) | 22 (43.1) | 0.056 | 0.813 |
| diabetes mellitus | 8 (22.9) | 12 (23.5) | 0.005 | 0.942 |
| cardiac disorders | 6 (17.1) | 16 (31.4) | 2.208 | 0.137 |
| MODS | 6 (17.1) | 10 (19.6) | 0.083 | 0.773 |
| malignancy | 6 (17.1) | 8 (15.7) | 0.032 | 0.857 |
| 3 or more underlying diseases | 14 (40.0) | 16 (31.4) | 0.680 | 0.410 |
| Invasive procedures | ||||
| CRRT | 13 (37.1) | 20 (39.2) | 0.038 | 0.846 |
| central venous catheter | 32 (91.4) | 45 (88.2) | 0.226 | 0.635 |
| foley catheter | 28 (80.0) | 41 (80.4) | 0.002 | 0.964 |
| nasogastric tube | 34 (97.1) | 46 (90.2) | 1.543 | 0.214 |
| recent surgery | 17 (48.6) | 21 (41.2) | 0.460 | 0.498 |
| Laboratory parameters | ||||
| APACHE II score | 20.40 ± 6.33 | 25.31 ± 7.28 | Z = −3.076 | 0.002 |
| C-reactive protein | 64.34 ± 61.14 | 73.18 ± 55.65 | Z = −1.174 | 0.241 |
| PCT | 7.267 ± 9.65 | 26.07 ± 56.32 | Z = −2.335 | 0.023 |
| proportion of XDR strains | 12 (34.3) | 18 (35.3) | 0.009 | 0.923 |
| Previous antibiotic used (within 1 month) | ||||
| sulbactam+ β-lactams | 16 (45.7) | 22 (43.1) | 0.056 | 0.813 |
| carbapenems | 28 (80.0) | 37 (72.5) | 0.624 | 0.429 |
| tigecycline | 2 (5.7) | 2 (3.9) | 0.150 | 0.698 |
| linezolid | 4 (11.4) | 5 (9.8) | 0.058 | 0.809 |
| fluoroquinolones | 10 (28.6) | 9 (17.6) | 1.439 | 0.230 |
| glycopeptides | 19 (54.3) | 24 (47.1) | 0.434 | 0.510 |
| cephalosporin | 4 (11.4) | 7 (13.7) | 0.098 | 0.754 |
| amikacin | 1 (2.9) | 2 (3.9) | 0.070 | 0.792 |
| used 3or more antibiotics | 17 (48.6) | 21 (41.2) | 0.460 | 0.498 |
| Antimicrobial therapy in the occurrence of BP | ||||
| sulbactam+ β-lactams | 15 (42.9) | 10 (19.6) | 5.441 | 0.020 |
| carbapenems | 25 (71.4) | 44 (86.3) | 2.884 | 0.089 |
| tigecycline | 6 (17.1) | 5 (9.8) | 1.002 | 0.317 |
| aminoglycosides | 2 (5.7) | 1 (2.0) | 0.869 | 0.351 |
| fluoroquinolones | 3 (8.6) | 5 (9.8) | 0.037 | 0.847 |
| Combination antimicrobial therapy | ||||
| tigecycline+sulbactam/β-lactam | 3 (8.6) | 2 (3.9) | 0.820 | 0.365 |
| carbapenems+sulbactam/β-lactams | 9 (25.7) | 8 (15.7) | 1.316 | 0.251 |
| appropriate antimicrobial therapy | 14 (40.0) | 12 (23.5) | 2.670 | 0.102 |
Data presented as mean ± standard deviation or n (%); ICU, intensive care units; MV, mechanical ventilation; ARDS, acute respiratory distress syndrome; COPD, chronic obstructive pulmonary disease ; MODS, multiple organ dysfunction syndrome; CRRT, continuous renal replacement therapy; APACHE, acute physiology and chronic health evaluation; PCT, procalcitonin; XDR, extensively drug-resistant.